Search

everythinglearnresearchcommunity

for

Search:↓

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

The new formulation greatly improved quercetin absorption in rats.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Epristeride's metabolism in zebrafish helps improve doping detection methods.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Upadacitinib may effectively treat resistant lichen planopilaris.

Ruxolitinib cream may help treat severe hair loss in children.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.

GLP-1 agonists may help treat certain skin conditions.